Hayashi Tatsuya, Suzuki Koji
Suzuka University of Medical Science, Faculty of Pharmaceutical Sciences, Suzuka-city, Mie 513-8670, Japan.
Cardiovasc Hematol Disord Drug Targets. 2015;15(1):2-9. doi: 10.2174/1871529x15666150108110821.
The process of blood coagulation is mediated by activation of a series of serine-protease zymogens. The protein C (PC) anticoagulant pathway, one of the important pathways related to physiological thrombosis formation, includes PC, thrombomodulin (TM), endothelial PC receptor (EPCR), protein S (PS) and C4b-binding protein (C4BP). TM, mainly present in endothelial cells, is a cofactor for thrombin-catalyzed activation of PC, and the resulting activated PC (aPC) inactivates the blood coagulation cofactors factor Va and factor VIIIa in the presence of PS. PS, mainly synthesized in hepatocytes and endothelial cells, plays a critical role as a cofactor of anticoagulant aPC in the regulation of blood coagulation. The cofactor activity of PS for aPC is regulated by C4BP, a multimeric protein whose structure consists of seven α-chains (C4BPα) and a β-chain (C4BPβ). Sepsis is generally caused by infection by microorganisms, and patients with sepsis undergo drastic hemostatic changes, thought to be induced by lipopolysaccharide (LPS) and inflammatory cytokines. In this review, based primarily on our previous studies, we describe the LPS- and cytokine-induced changes in various proteins in the PC anticoagulant pathway that are related to the increased risk of thrombosis under sepsis. Furthermore, we discuss the potential of recombinant soluble TM (rsTM) as a possible remedy for sepsis.
血液凝固过程由一系列丝氨酸蛋白酶原的激活介导。蛋白C(PC)抗凝途径是与生理性血栓形成相关的重要途径之一,包括PC、血栓调节蛋白(TM)、内皮细胞PC受体(EPCR)、蛋白S(PS)和C4b结合蛋白(C4BP)。TM主要存在于内皮细胞中,是凝血酶催化激活PC的辅因子,在PS存在的情况下,产生的活化PC(aPC)可使凝血辅因子因子Va和因子VIIIa失活。PS主要在肝细胞和内皮细胞中合成,作为抗凝aPC的辅因子在凝血调节中起关键作用。PS对aPC的辅因子活性受C4BP调节,C4BP是一种多聚体蛋白,其结构由七条α链(C4BPα)和一条β链(C4BPβ)组成。脓毒症通常由微生物感染引起,脓毒症患者会发生剧烈的止血变化,被认为是由脂多糖(LPS)和炎性细胞因子诱导的。在本综述中,主要基于我们之前的研究,我们描述了在脓毒症情况下,LPS和细胞因子诱导的PC抗凝途径中各种蛋白质的变化,这些变化与血栓形成风险增加有关。此外,我们讨论了重组可溶性TM(rsTM)作为脓毒症可能治疗方法的潜力。